Thermo Fisher Scientific Inc (TMO)
577.57
+2.98
(+0.52%)
USD |
NYSE |
Apr 24, 16:00
572.63
-4.94
(-0.86%)
After-Hours: 19:56
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 220.23B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 0.78% |
| Valuation | |
| PE Ratio | 37.38 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 5.229 |
| Price to Book Value | 4.712 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.39 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.7471 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 35.07% |
Profile
| Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of mid-2023 (revenue figures include some cross-segment revenue): analytical technologies (16% of sales); specialty diagnostic products (10%); life science solutions (24%); and lab products and services, which includes CRO services (54%). |
| URL | https://www.thermofisher.com |
| Investor Relations URL | https://ir.thermofisher.com |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Equity Style | Large Cap/Blend |
| Next Earnings Release | Apr. 24, 2024 |
| Last Earnings Release | Apr. 24, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Mar. 14, 2024 |
Ratings
Profile
| Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of mid-2023 (revenue figures include some cross-segment revenue): analytical technologies (16% of sales); specialty diagnostic products (10%); life science solutions (24%); and lab products and services, which includes CRO services (54%). |
| URL | https://www.thermofisher.com |
| Investor Relations URL | https://ir.thermofisher.com |
| HQ State/Province | Massachusetts |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Equity Style | Large Cap/Blend |
| Next Earnings Release | Apr. 24, 2024 |
| Last Earnings Release | Apr. 24, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Mar. 14, 2024 |